BigHat Biosciences Closes $75M Series C Financing to Advance AI-Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein Design
Insider Brief PRESS RELEASE — BigHat Biosciences, a clinical-stage, AI-driven protein therapeutics platform company, has announced the completion of a $75 million Series C financing, bringing its total funding raised to date to $223 million. The round was co-led by DFJ Growth Premji Invest with par…
Read the full story at AI Insider ↗